Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • ADC Antibody
    (1)
  • Antibody-Drug Conjugates (ADCs)
    (1)
  • Others
    (1)
TargetMol | Tags By Application
  • ELISA
    (2)
  • FCM
    (2)
  • Functional assay
    (2)
TargetMol | Tags By ResearchField
  • Cancer
    (2)
Filter
Search Result
Results for "

ladiratuzumab

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    2
    TargetMol | All_Pathways
  • Inhibitory Antibodies
    2
    TargetMol | Inhibitory_Antibodies
  • ADC/ADC Related
    2
    TargetMol | All_Pathways
Ladiratuzumab
hLIV22
T774151629760-28-6
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.
  • $263
In Stock
Size
QTY
Ladiratuzumab vedotin
SGN-LIV1A
T9901A-0441629760-29-7
Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) targeting LIV-1 (IC50: 5.6 nM), composed of a humanized monoclonal antibody, MMAE, and a protease-cleavable linker. It drives immunogenic cell death (ICD) to elicit an immune response and can be used in breast cancer research.
  • $558
In Stock
Size
QTY